NCT01058083

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

A Double-blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Primary Hypercholesterolemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	BMS-770767	Active, Oral, 15 mg, Daily, 28 days
DRUG	BMS-770767	Active, Oral, 50 mg, Daily, 28 days
DRUG	BMS-770767	Active, Oral, 150 mg, Daily, 28 days
DRUG	BMS-770767	Active, Oral, 50 mg BID, Daily, 28 days
DRUG	Placebo	Placebo, Oral, 0 mg, daily, 28 days

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-01-28
• Last updated: 2012-04-19

Locations

14 sites across 3 countries: United States, Australia, Canada